Overview

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2028-08-31

Target enrollment:

Participant gender:

Summary

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate